Viagra(sildenafil)
Granpidam, Liqrev, Mysildecard, Revatio, Sildenafil, Viagra, Vizarsin (sildenafil) is a small molecule pharmaceutical. Sildenafil was first approved as Viagra on 1998-03-27. It is used to treat pulmonary hypertension and vasculogenic impotence in the USA. It has been approved in Europe to treat erectile dysfunction and pulmonary hypertension. The pharmaceutical is active against cGMP-specific 3',5'-cyclic phosphodiesterase. In addition, it is known to target ATP-binding cassette sub-family C member 5, cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha', solute carrier organic anion transporter family member 2B1, and solute carrier organic anion transporter family member 1B3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Revatio, Sildenafil, Viagra (discontinued: Liqrev, Sildenafil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| liqrev | New Drug Application | 2024-05-28 |
| revatio | New Drug Application | 2024-12-18 |
| sildenafil | ANDA | 2025-03-13 |
| sildenafil citrate | ANDA | 2025-04-04 |
| sildenafil for oral suspension | ANDA | 2020-08-15 |
| viagra | New Drug Application | 2023-11-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
| vasculogenic impotence | EFO_1001234 | D018783 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SILDENAFIL CITRATE, REVATIO, VIATRIS | |||
| 2026-01-31 | M-287 | ||
HCPCS
Code | Description |
|---|---|
| S0090 | Sildenafil citrate, 25 mg |
Clinical
Clinical Trials
471 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 11 | 23 | 28 | 30 | 34 | 118 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 16 | 9 | 11 | 41 | 16 | 91 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 10 | 22 | 25 | 17 | 24 | 90 |
| Pulmonary arterial hypertension | D000081029 | — | — | 4 | 3 | 15 | 15 | 19 | 55 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | — | 7 | 12 | 10 | 30 |
| Healthy volunteers/patients | — | — | — | 16 | 1 | — | 1 | 1 | 19 |
| Heart failure | D006333 | EFO_0003144 | I50 | 2 | 4 | 11 | 4 | 1 | 19 |
| Fibrosis | D005355 | — | — | 4 | 10 | 4 | 2 | — | 15 |
| Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | 2 | 3 | 2 | 1 | 5 | 12 |
| Infertility | D007246 | EFO_0000545 | — | 2 | 4 | 2 | 4 | 2 | 11 |
Show 86 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 3 | 6 | 1 | — | — | 6 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | 1 | 2 | — | 1 | 4 |
| Congenital heart defects | D006330 | — | Q24.9 | — | — | 1 | — | 3 | 4 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | 3 | 2 | — | 1 | 4 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | 1 | 1 | — | — | 3 |
| Eisenmenger complex | D004541 | — | I27.83 | — | — | 2 | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | 1 | — | 1 | 3 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | 1 | 1 | 2 | — | — | 3 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 1 | 1 | — | — | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | 1 | 2 | — | — | 2 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain injuries | D001930 | — | S06.9 | 3 | 4 | — | — | 2 | 9 |
| Traumatic brain injuries | D000070642 | — | S06 | 2 | 3 | — | — | 2 | 7 |
| Psychological sexual dysfunctions | D020018 | — | F52.0 | 1 | 5 | — | — | — | 6 |
| Asphyxia | D001237 | — | R09.01 | 2 | 3 | — | — | 1 | 6 |
| Asphyxia neonatorum | D001238 | EFO_1000824 | P84 | 2 | 3 | — | — | 1 | 6 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | 2 | 2 | — | — | — | 4 |
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | 2 | 2 | — | — | — | 4 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | 2 | 2 | — | — | 1 | 4 |
| Brain diseases | D001927 | — | G93.40 | 2 | 3 | — | — | — | 4 |
| Post-concussion syndrome | D038223 | EFO_1001827 | F07.81 | 1 | 2 | — | — | — | 3 |
Show 62 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | 2 | 3 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 2 | — | — | — | — | 2 |
| Embolism | D004617 | — | — | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | 1 | 2 |
| Female genital neoplasms | D005833 | — | — | 1 | — | — | — | 1 | 2 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | 1 | — | — | — | 1 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 2 | — | — | — | — | 2 |
| Vascular remodeling | D066253 | — | — | 1 | — | — | — | 1 | 2 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | 1 | — | — | — | 1 | 2 |
| Alopecia | D000505 | — | L64 | 1 | — | — | — | 1 | 2 |
Show 27 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hereditary congenital and neonatal diseases and abnormalities | D009358 | — | — | — | — | — | — | 2 | 2 |
| Pregnancy complications | D011248 | — | — | — | — | — | — | 2 | 2 |
| High-risk pregnancy | D018566 | — | — | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Iron overload | D019190 | — | — | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Penile neoplasms | D010412 | — | C60 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Trisomy | D014314 | — | Q92.2 | — | — | — | — | 1 | 1 |
Show 36 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sildenafil |
| INN | sildenafil |
| Description | Sildenafil, sold under the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension.It is also sometimes used off-label for the treatment of certain symptoms in secondary Raynaud's phenomenon. It is unclear if it is effective for treating sexual dysfunction in women. It can be taken orally (swallowed by mouth), intravenously (injection into a vein), or sublingually (dissolved under the tongue). Onset when taken orally is typically within twenty minutes and lasts for about two hours.
|
| Classification | Small molecule |
| Drug class | phosphodiesterase type 5 inhibitors (PDE5) inhibitors: (PDE5) inhibitors containing a sulfonamide moiety |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12 |
Identifiers
| PDB | — |
| CAS-ID | 139755-83-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL192 |
| ChEBI ID | 9139 |
| PubChem CID | 5212 |
| DrugBank | DB00203 |
| UNII ID | 3M7OB98Y7H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLCO2B1
SLCO2B1
Organism
Homo sapiens
Gene name
SLCO2B1
Gene synonyms
KIAA0880, OATP2B1, OATPB, SLC21A9
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 2B1
Protein synonyms
OATP-B, OATP-RP2, OATP2B1, OATPRP2, Organic anion transporter B, Organic anion transporter polypeptide-related protein 2, Organic anion transporting polypeptide 2B1, solute carrier family 21 (organic anion transporter), member 9, Solute carrier family 21 member 9
Uniprot ID
Mouse ortholog
Slco2b1 (101488)
solute carrier organic anion transporter family member 2B1 (Q8BXB6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Viagra – Viatris
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Viagra – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Revatio – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Sildenafil – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Sildenafil
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 23,078 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
58,600 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use